Human 8-Cell Embryos Enable Efficient Induction of Disease-Preventive Mutations Without Off-Target Effect by Cytosine Base Editor

Yinghui Wei,Meiling Zhang,Jing Hu,Yingsi Zhou,Mingxing Xue,Jianhang Yin,Yuanhua Liu,Hu Feng,Ling Zhou,Zhifang Li,Dongshuang Wang,Zhiguo Zhang,Yin Zhou,Hongbin Liu,Ning Yao,Erwei Zuo,Jiazhi Hu,Yanzhi Du,Wen Li,Chunlong Xu,Hui Yang
DOI: https://doi.org/10.1093/procel/pwac043
2023-01-01
Protein & Cell
Abstract:Approximately 140 million people worldwide are homozygous carriers of APOE4 (epsilon 4), a strong genetic risk factor for late onset familial and sporadic Alzheimer's disease (AD), 91% of whom will develop AD at earlier age than heterozygous carriers and noncarriers. Susceptibility to AD could be reduced by targeted editing of APOE4, but a technical basis for controlling the off-target effects of base editors is necessary to develop low-risk personalized gene therapies. Here, we first screened eight cytosine base editor variants at four injection stages (from 1- to 8-cell stage), and found that FNLS-YE1 variant in 8-cell embryos achieved the comparable base conversion rate (up to 100%) with the lowest bystander effects. In particular, 80% of AD-susceptible epsilon 4 allele copies were converted to the AD-neutral epsilon 3 allele in human epsilon 4-carrying embryos. Stringent control measures combined with targeted deep sequencing, whole genome sequencing, and RNA sequencing showed no DNA or RNA off-target events in FNLS-YE1-treated human embryos or their derived stem cells. Furthermore, base editing with FNLS-YE1 showed no effects on embryo development to the blastocyst stage. Finally, we also demonstrated FNLS-YE1 could introduce known protective variants in human embryos to potentially reduce human susceptivity to systemic lupus erythematosus and familial hypercholesterolemia. Our study therefore suggests that base editing with FNLS-YE1 can efficiently and safely introduce known preventive variants in 8-cell human embryos, a potential approach for reducing human susceptibility to AD or other genetic diseases.
What problem does this paper attempt to address?